152 related articles for article (PubMed ID: 37739233)
21. [Characteristics, multimodality imaging and treatment of macular telangiectasia type 2].
Cai Y; Shi X; Zhao MW; Li XX
Zhonghua Yan Ke Za Zhi; 2019 Jan; 55(1):68-73. PubMed ID: 30641677
[TBL] [Abstract][Full Text] [Related]
22. EARLY SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY BIOMARKERS TO CONFIRM FELLOW EYE CHANGES IN ASYMMETRIC TYPE-2 MACULAR TELANGIECTASIA: A Case-Control Study (India Macular Telangiectasia Report 1).
Alex D; Giridhar A; Gopalakrishnan M; Manayath G; Amar S; Raman R; Sreenivasan R; Ayachit A; Sivaprasad S
Retina; 2021 Mar; 41(3):471-479. PubMed ID: 32804830
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of cystoid spaces in type 2 idiopathic macular telangiectasia on spectral domain optical coherence tomography images.
Oh JH; Oh J; Togloom A; Kim SW; Huh K
Retina; 2014 Jun; 34(6):1123-31. PubMed ID: 24240556
[TBL] [Abstract][Full Text] [Related]
24. Swept source optical coherence tomography analysis of choroidal thickness in macular telangiectasia type 2: a case-control study.
Kumar V; Kumawat D; Kumar P
Graefes Arch Clin Exp Ophthalmol; 2019 Mar; 257(3):567-573. PubMed ID: 30560414
[TBL] [Abstract][Full Text] [Related]
25. Right-angled vessel characteristics in different stages of type 2 macular telangiectasia (MacTel).
Venkatesh R; Handa A; Chitturi SP; Choudhary A; Prabhu V; Acharya I; Mangla R; Yadav NK; Chhablani J
Eye (Lond); 2024 Apr; 38(6):1162-1167. PubMed ID: 38012385
[TBL] [Abstract][Full Text] [Related]
26. Outer retinal hyperreflective spots on spectral-domain optical coherence tomography in macular telangiectasia type 2.
Baumüller S; Charbel Issa P; Scholl HP; Schmitz-Valckenberg S; Holz FG
Ophthalmology; 2010 Nov; 117(11):2162-8. PubMed ID: 20557944
[TBL] [Abstract][Full Text] [Related]
27. FLUORESCENCE LIFETIME IMAGING OPHTHALMOSCOPY IN PATIENTS WITH MACULAR TELANGIECTASIA TYPE 2 WITH AND WITHOUT DIABETES.
Sauer L; Vitale AS; Jacoby RS; Hart B; Bernstein PS
Retina; 2023 Sep; 43(9):1597-1607. PubMed ID: 37263186
[TBL] [Abstract][Full Text] [Related]
28. Anti-retinal IgG antibodies in patients with early and advanced type 2 macular telangiectasia.
McLenachan S; Balaratnasingam C; Heath Jeffery RC; Chen SC; Zhang D; Chan G; Dolz-Marco R; Bacci T; Lo J; Wiffen S; Yannuzzi LA; Chen FK
Exp Eye Res; 2022 May; 218():109024. PubMed ID: 35271830
[TBL] [Abstract][Full Text] [Related]
29. Characteristics and quantification of vascular changes in macular telangiectasia type 2 on optical coherence tomography angiography.
Chidambara L; Gadde SG; Yadav NK; Jayadev C; Bhanushali D; Appaji AM; Akkali M; Khurana A; Shetty R
Br J Ophthalmol; 2016 Nov; 100(11):1482-1488. PubMed ID: 26823394
[TBL] [Abstract][Full Text] [Related]
30. Fundus Autofluorescence Imaging in Macular Telangiectasia Type 2: MacTel Study Report Number 9.
Pauleikhoff L; Heeren TFC; Gliem M; Lim E; Pauleikhoff D; Holz FG; Clemons T; Balaskas K; ; Egan CA; Charbel Issa P
Am J Ophthalmol; 2021 Aug; 228():27-34. PubMed ID: 33775659
[TBL] [Abstract][Full Text] [Related]
31. Choroidal vascularity index: an enhanced depth optical coherence tomography-based parameter to determine vascular status in patients with proliferative and non-proliferative macular telangiectasia.
Karasu B; Celebi ARC
Int Ophthalmol; 2021 Oct; 41(10):3505-3513. PubMed ID: 34181193
[TBL] [Abstract][Full Text] [Related]
32. Ultrastructural and clinical evidence of subretinal debris accumulation in type 2 macular telangiectasia.
Cherepanoff S; Killingsworth MC; Zhu M; Nolan T; Hunyor AP; Young SH; Hageman GS; Gillies MC
Br J Ophthalmol; 2012 Nov; 96(11):1404-9. PubMed ID: 22976584
[TBL] [Abstract][Full Text] [Related]
33. Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2.
Pauleikhoff D; Bonelli R; Dubis AM; Gunnemann F; Rothaus K; Charbel Issa P; Heeren TF; Peto T; Clemons TE; Chew EY; Bird AC; Sallo FB;
Acta Ophthalmol; 2019 Nov; 97(7):e998-e1005. PubMed ID: 30968592
[TBL] [Abstract][Full Text] [Related]
34. Automatic diagnosis of macular diseases from OCT volume based on its two-dimensional feature map and convolutional neural network with attention mechanism.
Sun Y; Zhang H; Yao X
J Biomed Opt; 2020 Sep; 25(9):. PubMed ID: 32940026
[TBL] [Abstract][Full Text] [Related]
35. Retinal vascular density evaluated by optical coherence tomography angiography in macular telangiectasia type 2.
Dogan B; Erol MK; Akidan M; Suren E; Akar Y
Int Ophthalmol; 2019 Oct; 39(10):2245-2256. PubMed ID: 30607862
[TBL] [Abstract][Full Text] [Related]
36. Optical coherence tomography-angiography for monitoring neovascularisations in macular telangiectasia type 2.
Tzaridis S; Hess K; Friedlander M; Holz FG
Br J Ophthalmol; 2021 May; 105(5):735-740. PubMed ID: 32513667
[TBL] [Abstract][Full Text] [Related]
37. Does size of telangiectasia on optical coherence tomography angiography influence vision in eyes with type 2 macular telangiectasia?
Kelkar AS; Kelkar JA; Tidke S; Agarwal A; Bolisetty M; Kelkar S
Indian J Ophthalmol; 2021 Dec; 69(12):3570-3576. PubMed ID: 34826997
[TBL] [Abstract][Full Text] [Related]
38. The preproliferative stage in type 2 macular telangiectasia (MacTel type 2).
Venkatesh R; Reddy NG; Mishra P; Pereira A; Mutalik D; Agrawal S; Bhatt A; Yadav NK; Chhablani J
Graefes Arch Clin Exp Ophthalmol; 2022 Jan; 260(1):121-132. PubMed ID: 34410484
[TBL] [Abstract][Full Text] [Related]
39. Relative Ellipsoid Zone Reflectivity in Macular Telangiectasia Type 2.
Goerdt L; Weinhold L; Isselmann B; Garcia JLR; Künzel SH; Schmid M; Holz FG; Tzaridis S; Thiele S
Invest Ophthalmol Vis Sci; 2023 Jul; 64(10):21. PubMed ID: 37462978
[TBL] [Abstract][Full Text] [Related]
40. UD-MIL: Uncertainty-Driven Deep Multiple Instance Learning for OCT Image Classification.
Wang X; Tang F; Chen H; Luo L; Tang Z; Ran AR; Cheung CY; Heng PA
IEEE J Biomed Health Inform; 2020 Dec; 24(12):3431-3442. PubMed ID: 32248132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
